List of Excipients in Branded Drug LUMRYZ

LUMRYZ Excipient Strategy, Patent Protection, and Commercial Opportunities

Last updated: August 25, 2026

LUMRYZ is a once-nightly extended-release sodium oxybate product for adults with narcolepsy. Its commercial differentiation depends on controlled release from a high-drug-load powder, single-dose administration, and a tightly controlled distribution model. The excipient strategy is therefore central to product performance, generic development risk, manufacturing reliability, and lifecycle management.

LUMRYZ was approved by the U.S. Food and Drug Administration in May 2023 under NDA 214755. Avadel Pharmaceuticals developed the product as an extended-release oral suspension supplied in unit-dose packets containing 4.5 g, 6 g, 7.5 g, or 9 g of sodium oxybate [1].

What excipients are used in LUMRYZ?

LUMRYZ uses a solid oral powder that is mixed with water before administration. The formulation contains sodium oxybate as the active pharmaceutical ingredient and a controlled-release excipient system based on hydrophilic polymers and pharmaceutical processing aids.

Public FDA labeling identifies the product as an extended-release oral suspension and lists inactive ingredients that include hypromellose, microcrystalline cellulose, colloidal silicon dioxide, and other tableting or powder-processing excipients, depending on the presentation and manufacturing specification [1].

Formulation element	Likely technical function	Commercial significance
Sodium oxybate	Active ingredient	High-dose drug load drives packet size and manufacturing economics
Hypromellose	Hydrophilic release-controlling polymer	Controls hydration, gel formation, and oxybate release
Microcrystalline cellulose	Diluent, carrier, and structural excipient	Supports powder handling and content uniformity
Colloidal silicon dioxide	Glidant and flow aid	Improves packet filling and dose uniformity
Lubricant or processing aid	Reduces adhesion and improves manufacturing flow	Affects scale-up, equipment selection, and control strategy
Water added before dosing	Reconstitution medium	Enables a dry, stable product while maintaining patient usability

The formulation challenge is unusually demanding. Sodium oxybate is highly water-soluble and is administered at gram-level doses. A conventional immediate-release powder would dissolve rapidly and would not provide the overnight exposure profile required for once-nightly dosing. The excipient system must slow drug release without creating an unacceptably large dose, excessive viscosity, poor dispersion, or variable dose delivery.

How does the LUMRYZ excipient strategy control drug release?

LUMRYZ relies on a hydrophilic matrix approach. After water is added, the polymer hydrates and forms a viscous gel or diffusion barrier. Sodium oxybate then moves through the hydrated matrix at a controlled rate.

The release profile depends on several interacting variables:

1. Polymer molecular weight and substitution characteristics.
2. Polymer concentration relative to sodium oxybate.
3. Particle-size distribution.
4. Powder porosity and agglomeration.
5. Reconstitution volume and mixing conditions.
6. Ionic strength and pH of the resulting suspension.
7. Manufacturing shear and blending uniformity.

Hypromellose is commercially available in multiple viscosity grades. Substituting one grade for another can materially change hydration rate, gel strength, release kinetics, suspension behavior, and bioavailability. A generic developer cannot assume that an interchangeable hypromellose grade will reproduce the reference product.

The high active load also limits formulation freedom. Increasing polymer concentration may slow release but can increase suspension viscosity and make the product difficult to mix or swallow. Reducing polymer concentration may improve handling but create dose dumping or an insufficient overnight profile.

What commercial opportunities exist for LUMRYZ excipient suppliers?

The principal opportunity is not the sale of commodity excipients alone. It is the supply of qualified, tightly controlled excipient grades supported by technical documentation, consistency data, and manufacturing-change management.

Premium hypromellose grades

Hypromellose is the most commercially important excipient in the formulation. Potential suppliers can compete on:

• Narrow viscosity distribution.
• Consistent substitution pattern.
• Low bioburden and controlled microbial quality.
• Particle-size engineering.
• Low variability in hydration and gel formation.
• Documentation supporting pharmaceutical regulatory filings.
• Dual-site or regional supply security.

A supplier that can demonstrate formulation-specific equivalence across multiple manufacturing lots has greater value than a supplier offering a nominally similar compendial grade.

Co-processed excipient systems

Co-processed cellulose and polymer systems could improve powder flow, reduce segregation, and support more efficient packet filling. The opportunity is constrained by the need to preserve dissolution performance and avoid introducing a new patentable or regulatory-sensitive formulation variable.

Potential applications include:

• Improved flow at high active loading.
• Reduced electrostatic charging.
• Better uniformity during blending.
• Lower packet-fill weight variation.
• Faster wetting after reconstitution.
• Reduced clumping during storage.

Any co-processed excipient would face substantial development work because the product is an extended-release dosage form rather than a conventional immediate-release powder.

Silica and flow-control systems

Colloidal silicon dioxide and related glidants can improve powder movement through feeders and filling equipment. The commercial value lies in optimizing flow without causing segregation or altering wetting behavior.

Excessive glidant can produce dusting, affect suspension texture, or interfere with powder cohesion. Insufficient glidant can cause filling variability and manufacturing stoppages. The commercially relevant specification is therefore formulation-specific rather than purely compendial.

Packaging and moisture-control materials

LUMRYZ is supplied as a dry powder in unit-dose packets. Packaging suppliers can pursue opportunities in:

• High-barrier laminate structures.
• Moisture ingress control.
• Seal integrity.
• Child-resistant secondary packaging.
• Unit-dose dispensing systems.
• Compatibility with automated filling and serialization.
• Reduced packaging volume for specialty-pharmacy distribution.

Because the product is reconstituted immediately before dosing, the package must protect the dry matrix from moisture without creating difficult opening or powder-retention problems.

What patents protect the LUMRYZ formulation?

LUMRYZ protection is expected to rely on a combination of formulation, controlled-release, dosing, manufacturing, and regulatory exclusivity rights. The commercially relevant claims are likely to include:

• Extended-release sodium oxybate compositions.
• High-load oral dosage forms.
• Polymer-controlled release matrices.
• Once-nightly administration.
• Pharmacokinetic profiles that maintain overnight exposure.
• Methods of treating narcolepsy with reduced dosing frequency.
• Manufacturing processes for producing a uniform extended-release powder.
• Unit-dose packaging and reconstitution procedures.

The strongest claims are generally those that connect composition to a measurable release or pharmacokinetic result. A broad claim covering sodium oxybate plus a generic polymer may face more prior-art exposure than a claim requiring specific polymer ratios, release windows, particle attributes, or pharmacokinetic parameters.

Excipient suppliers should assess whether their products are merely raw materials or are incorporated into claims directed to:

• Specific polymer viscosity ranges.
• Defined excipient-to-drug ratios.
• Particle-size limits.
• Controlled-release dissolution profiles.
• Specific manufacturing conditions.
• Reconstituted suspension characteristics.

A supplier’s freedom to operate can differ materially depending on whether it sells an excipient to Avadel, develops a competing finished product, or markets a formulation platform to a generic applicant.

When does LUMRYZ lose exclusivity?

FDA exclusivity and patent expiry are separate events.

Protection category	LUMRYZ relevance
New chemical entity exclusivity	Limited relevance because sodium oxybate was previously approved in other products
New formulation or clinical exclusivity	Potentially relevant depending on the specific FDA grant
Orphan-drug exclusivity	Potentially relevant if the approved indication and designation satisfy orphan requirements
Orange Book patents	May delay an approved ANDA if a listed patent is properly challenged
REMS and controlled-substance controls	Can increase market-entry complexity but do not independently create patent exclusivity
Trade secrets	May protect process parameters, specifications, and scale-up knowledge beyond published claims

The practical generic-entry date depends on the latest enforceable patent, the timing of Paragraph IV litigation, any settlement, and the commercial feasibility of demonstrating bioequivalence for a complex extended-release product.

A patent expiration date should not be treated as an automatic launch date. Generic developers must also address controlled-release performance, fed and fasted pharmacokinetics, dose proportionality, food effects, powder reconstitution, and the regulatory requirements applicable to sodium oxybate products.

What is the Orange Book status of LUMRYZ?

LUMRYZ is approved as an NDA product and is subject to FDA listing and patent-certification rules applicable to drug products in the Orange Book [2]. Orange Book-listed patents can support a patent-certification strategy by an ANDA applicant.

A Paragraph IV certification would assert that a listed patent is invalid, unenforceable, or not infringed. If the NDA holder files a patent-infringement action within the statutory period, FDA approval of the ANDA can be subject to a 30-month stay, subject to court decisions and statutory exceptions [3].

The relevant diligence questions are:

• Which LUMRYZ patents are currently listed?
• Which claims cover the finished dosage form rather than a broad platform?
• Do the claims require specific excipient ratios?
• Are method-of-use claims directed to narcolepsy treatment?
• Has any ANDA applicant submitted a Paragraph IV certification?
• Has Avadel filed infringement litigation?
• Are any settlements subject to Federal Trade Commission review or public disclosure?
• Are pediatric, orphan, or other regulatory exclusivities still active?

A current Orange Book review and litigation-docket search are required for a definitive launch forecast. Publicly available approval materials establish the regulatory status, but they do not by themselves determine the commercial enforceability of every formulation claim.

What generic entry risks exist for LUMRYZ?

Generic entry risk is moderate to high in technical complexity and potentially high in legal sensitivity.

Bioequivalence risk

Sodium oxybate products have different release profiles and dosing schedules. A generic developer may need to demonstrate that its product reproduces the reference product’s exposure profile rather than merely matching the active ingredient.

Key risk areas include:

• Early-release sodium oxybate exposure.
• Total exposure over the dosing interval.
• Overnight concentration maintenance.
• Food-effect sensitivity.
• Dose proportionality across strengths.
• Suspension uniformity after reconstitution.
• Variability caused by incomplete mixing.

Formulation-design risk

A developer that changes hypromellose grade, cellulose grade, particle size, or manufacturing process may produce a product with unacceptable release differences. The active ingredient is relatively simple chemically, but the dosage form is not simple from a regulatory perspective.

Controlled-substance risk

Sodium oxybate is subject to controlled-substance restrictions and abuse-prevention controls. LUMRYZ is distributed through a restricted program that includes prescriber and pharmacy controls [1]. A generic product would need a compliant risk-management and distribution structure. This can raise launch costs and reduce the number of capable entrants.

Manufacturing risk

The product requires consistent high-dose powder handling. Scale-up risks include blend segregation, feeder variability, dust control, electrostatic behavior, and packet-fill accuracy. A developer may need dedicated equipment or specialized process controls.

How does LUMRYZ compare with XYREM and XYWAV?

Attribute	LUMRYZ	XYREM	XYWAV
Active ingredient	Sodium oxybate	Sodium oxybate	Calcium, magnesium, potassium, and sodium oxybates
Dosing schedule	Once nightly	Divided nightly doses	Divided nightly doses
Dosage form	Extended-release oral suspension powder	Oral solution	Oral solution
Sodium burden	High	High	Lower sodium relative to sodium oxybate
Primary commercial differentiation	Convenience and once-nightly dosing	Established sodium oxybate franchise	Lower-sodium oxybate formulation
Excipient opportunity	Controlled-release matrix and powder handling	Solution stability and taste-related formulation	Multi-cation salt system and solution formulation
Generic complexity	High	Lower formulation complexity, but controlled-substance barriers remain	High due to mixed oxybate composition

LUMRYZ competes primarily on dosing convenience. XYWAV competes on reduced sodium exposure. XYREM retains the advantage of commercial history and physician familiarity. The excipient strategy therefore supports a product-positioning claim that is clinically and commercially relevant: a dry, once-nightly extended-release formulation rather than a liquid requiring multiple nightly doses.

What licensing opportunities exist around LUMRYZ excipients?

Licensing opportunities are most credible in four areas.

Controlled-release polymer technology

A polymer supplier with proprietary grades, particle engineering, or matrix-formulation know-how could license technology for:

• Sodium oxybate release control.
• High-solubility drug delivery.
• Once-nightly oral products.
• Reduced-volume reconstitution.
• Improved suspension uniformity.

Manufacturing process technology

Process licensing could address continuous blending, low-shear granulation, dry coating, packet filling, and in-line content-uniformity monitoring.

Packaging technology

Barrier films, moisture scavengers, dispensing systems, and child-resistant packet designs could be licensed to improve stability, usability, or supply-chain economics.

Generic-enabling technologies

A platform that produces equivalent release from alternative excipient grades could help generic applicants reduce development time. This opportunity is legally sensitive because the platform must be assessed against formulation and process patent claims before commercialization.

How strong is the LUMRYZ patent estate?

The estate’s commercial strength depends less on the number of patents than on claim scope and the ability to connect the claims to a competing product.

The strongest protection would generally include:

• Claims limited to a once-nightly extended-release sodium oxybate product.
• Defined dissolution or pharmacokinetic performance.
• Specific excipient composition or polymer ranges.
• Claims that cover all commercially practical formulation routes.
• Manufacturing claims that are difficult to design around.
• Method-of-use claims aligned with the approved indication.

The estate is weaker if competitors can achieve the same clinical profile using different polymers, different matrix architecture, or a non-infringing manufacturing route. High formulation complexity can still create a practical barrier even where the patent position is not absolute.

Key Takeaways

• LUMRYZ’s commercial value depends on a high-drug-load, polymer-controlled extended-release matrix.
• Hypromellose is the central excipient opportunity because grade, viscosity, hydration, and particle characteristics affect release performance.
• Microcrystalline cellulose, colloidal silicon dioxide, lubricants, and packaging materials support manufacturability and dose uniformity.
• Generic entry is technically difficult because sodium oxybate is highly soluble, administered at gram-level doses, and subject to controlled-substance restrictions.
• Patent risk is likely concentrated in formulation composition, release profile, once-nightly dosing, manufacturing, and method-of-use claims.
• Excipient suppliers have the greatest opportunity in qualified polymer grades, co-processed systems, high-barrier packaging, and generic-enabling formulation platforms.
• LUMRYZ competes with XYREM on dosing frequency and with XYWAV on product differentiation, while retaining a higher sodium burden than XYWAV.
• FDA approval, Orange Book listings, Paragraph IV activity, and any settlement terms determine the practical generic-entry timetable.

Frequently Asked Questions

Can LUMRYZ be reformulated with a different hypromellose grade?

Possibly, but a different hypromellose grade can alter dissolution, suspension viscosity, reconstitution behavior, and pharmacokinetics. A substitution would require formulation and bioequivalence assessment.

Is LUMRYZ an extended-release tablet?

No. LUMRYZ is supplied as a powder for oral suspension. The patient mixes the packet contents with water before administration [1].

Do excipient suppliers need a license from Avadel to sell hypromellose?

Not necessarily. A compendial excipient can generally be sold independently, but formulation use may implicate patents, proprietary specifications, quality agreements, or supply contracts.

Could a generic use a non-polymer extended-release technology?

A non-polymer technology could be developed, but it would need to reproduce the reference product’s release and exposure profile while avoiding applicable composition, process, and method patents.

Does the LUMRYZ REMS prevent generic competition?

No. A REMS does not independently block approval of a generic. It can increase development, distribution, compliance, and launch costs.

References

1. U.S. Food and Drug Administration. (2023). LUMRYZ (sodium oxybate) extended-release oral suspension: Prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA.

3. U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs. Cornell Law School, Legal Information Institute.

4. U.S. Food and Drug Administration. (2023). FDA approves new once-nightly treatment for narcolepsy. FDA.

5. Avadel Pharmaceuticals plc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.